CTI BioPharma Announces Proposed Public Offering of Convertible Preferred Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
CTI BioPharma (CTIC) Announces Pricing of 50,000 Share Series N-1 Conv. Preferred Stock Offering
October 27, 2015 9:13 AM EDTCTI BioPharma (NASDAQ: CTIC) announced the pricing of an underwritten public offering of 50,000 shares of its Series N-1 Preferred Stock, offered at a price to the public of $1,000 per share of Series N-1 Preferred Stock (the "Offering"). Each share of Series N-1 Preferred Stock is convertible at the option of the holder, at any time, into 800 shares of common stock at... More
CTI BioPharma (CTIC) Plans Conv. Preferred Offering
October 26, 2015 4:34 PM EDTCTI BioPharma (NASDAQ: CTIC) announced that it intends to offer and sell, subject to market and other conditions, shares of its Series N-1 Preferred Stock in an underwritten public offering (the "Offering"). Each share of Series N-1 Preferred Stock will have a... More
